Clinical Trial Search

Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…

Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants

Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer

Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants

Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…

Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…

Primary: Number of Subjects With Immediate Adverse Events — 0; 0 Participants

Primary: Hemagglutination Inhibition Antibody (HIA) Titer for Each of the Three Antigens Contained in the Vaccine — 269.7; 337.3; 288.5; 297.1 Titers

Primary: Hemagglutination Inhibition (HI) Antibody Titer — 10.2; 8.7; 314.1; 89.4 titer

Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…

Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf — 17; 36; 95; 80…

Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants

Primary: HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination — 175; 117; 144; 118 Titer

Primary: Percentage of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVf — 83; 60; 70; 48…

Primary: Geometric Mean Titers (GMTs) of Anti-H3 and B Strains — 369.6; 331.2; 269.6; 245.0 Titer

Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases

Primary: Number of Participants With Solicited Adverse Events (Local & Systemic Reactogenicity) — 5; 1; 5; 0 Participants

Primary: Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV). — 22; 23; 624; 199 Titer

Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres

Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV — 52; 41; 100; 78…

Primary: Number of Participants With Adverse Events — 5; 8; 69; 30 Participants

Primary: Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route — 142; 116…

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 1.7; 0.4 Percentage of participants

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0 Percentage of Participants

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer

Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases

Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV — 46; 89; 43; 90…

Primary: Percentages of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of aTIV — 59; 65; 81…

Primary: Seroprotection — 94.5; 100; 100; 100 percentage of subjects